Archive for October, 2004

Biotech: The “safe” drug bet?

Biotech: The “safe” drug bet? “Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”


Click here for reuse options!
Copyright 2004 Biotechblog

Biotech execs have a sense of humor about elusive profits

Biotech execs have a sense of humor about elusive profits When Ernst & Young’s annual report on the biotechnology industry last year predicted that as a whole, the industry would turn profitable for the first time in 2008, some long-term industry veterans gave a knowing heard-that-one-before chuckle.


Click here for reuse options!
Copyright 2004 Biotechblog

Foresight or folly? Generics firms' foray into NCEs

Foresight or folly? Generics firms’ foray into NCEs A number of generics firms have, over the last few years, veered off the path and started to develop innovative drugs in their own right. In a time when generics firms are showing the greatest growth in the pharmaceutical sector, what has driven them to venture into […]


Click here for reuse options!
Copyright 2004 Biotechblog

Foresight or folly? Generics firms’ foray into NCEs

Foresight or folly? Generics firms’ foray into NCEs A number of generics firms have, over the last few years, veered off the path and started to develop innovative drugs in their own right. In a time when generics firms are showing the greatest growth in the pharmaceutical sector, what has driven them to venture into […]


Click here for reuse options!
Copyright 2004 Biotechblog

How many trillions for a drug miracle?

How many trillions for a drug miracle? “Here’s a quick thought experiment about the current system for developing and paying for miracle drugs: Would it be worth almost any price to develop a drug with a better than 50-50 probability of conquering many of the world’s most deadly diseases? “


Click here for reuse options!
Copyright 2004 Biotechblog

State biotech sector no miracle drug for creation of jobs

State biotech sector no miracle drug for creation of jobs “Ruth Scott’s job is to be the No. 1 cheerleader for biotechnology in Washington state. But when politicians talk up the industry as a silver bullet for job growth, she cringes.”


Click here for reuse options!
Copyright 2004 Biotechblog

Merck: Successor pill safer than Vioxx

Merck: Successor pill safer than Vioxx Merck & Co., the US drug maker that recalled its Vioxx painkiller because of a link to heart disease, said short-term studies show the company�s planned successor pill, Arcoxia, is safer.


Click here for reuse options!
Copyright 2004 Biotechblog

%d bloggers like this: